1 Baskar R, Lee KA, Yeo R, Yeoh KW. Cancer and radiation therapy: Current advances and future directions. International Journal of Medical Sciences. 2012;9: 193–9. 2012. p.
2 Definition of immunotherapy – NCI Dictionary of Cancer Terms – National Cancer Institute [Internet]. [cited 2019 Oct 21]. Available from:
https://www.cancer.gov/publications/dictionaries/cancer-terms/def/immunotherapy
3 Shields BD, Mahmoud F, Taylor EM, Byrum SD, Sengupta D, Koss B, et al. Indicators of responsiveness to immune checkpoint inhibitors. Sci Rep [Internet]. 2017;7(March):1–12. Available from:
http://dx.doi.org/10.1038/s41598-017-01000-2
4 Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A, et al. Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer. N Engl J Med [Internet]. 2016 Nov 10 [cited 2019 Nov 17];375(19):1823–33. Available from:
http://www.nejm.org/doi/10.1056/NEJMoa1606774
5 Füreder T. Immuntherapie in der Onkologie. Wien Klin Wochenschr. 2017;(12):17–33.
6 Chen DS, Mellman I. Oncology meets immunology: the cancer-Immunity cycle. Immunity. 2013;(39):1–10.
7 Mole RH. Whole body irradiation — radiobiology or medicine? 1953;XXVI(305):234–41.
8 Galluzzi L, Buqué A, Kepp O, Zitvogel L, Kroemer G. Immunogenic cell death in cancer and infectious disease. Nat Rev Immunol [Internet]. 2017;17(2):97–111. Available from:
http://dx.doi.org/10.1038/nri.2016.107
9 Derer A, Deloch L, Rubner Y, Fietkau R, Frey B, Gaipl US. Radio-Immunotherapy-Induced Immunogenic Cancer Cells as Basis for Induction of Systemic Anti-Tumor Immune Responses – Pre-Clinical Evidence and Ongoing Clinical Applications. Front Immunol [Internet]. 2015 [cited 2019 Oct 27];6:505. Available from:
http://www.ncbi.nlm.nih.gov/pubmed/26500646
10 Rodríguez-Ruiz ME, Vanpouille-Box C, Melero I, Formenti SC, Demaria S. Immunological Mechanisms Responsible for Radiation-Induced Abscopal Effect. Trends Immunol [Internet]. 2018;39(8):644–55. Available from:
https://doi.org/10.1016/j.it.2018.06.001
11 Chicas-Sett R, Morales-Orue I, Rodriguez-Abreu D, Lara-Jimenez P. Combining radiotherapy and ipilimumab induces clinically relevant radiation-induced abscopal effects in metastatic melanoma patients: A systematic review. Clin Transl Radiat Oncol [Internet]. 2018;9:5–11. Available from:
https://doi.org/10.1016/j.ctro.2017.12.004
12 Asna N, Livoff A, Batash R, Debbi R, Schaffer P, Rivkind T, et al. Radiation therapy and immunotherapy— A potential combination in cancer treatment. Curr Oncol. 2018;25(5):e454–60.
13 Weichselbaum RR, Liang H, Deng L, Fu YX. Radiotherapy and immunotherapy: A beneficial liaison? Nat Rev Clin Oncol [Internet]. 2017;14(6):365–79. Available from:
http://dx.doi.org/10.1038/nrclinonc.2016.211
14 Nguyen N, Bellile E, Thomas D, McHugh J, Rozek L, Virani S, et al. Tumor infiltrating lymphocytes and survival in patients with head and neck squamous cell carcinoma. Head Neck [Internet]. 2016 [cited 2019 Oct 27];38(7):1074–84. Available from:
http://www.ncbi.nlm.nih.gov/pubmed/26879675
15 Loi S, Sirtaine N, Piette F, Salgado R, Viale G, Van Eenoo F, et al. Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. J Clin Oncol [Internet]. 2013 Mar 1 [cited 2019 Oct 27];31(7):860–7. Available from:
http://www.ncbi.nlm.nih.gov/pubmed/23341518
16 Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pagès C, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science [Internet]. 2006 Sep 29 [cited 2019 Oct 27];313(5795):1960–4. Available from:
http://www.ncbi.nlm.nih.gov/pubmed/17008531
17 Sharabi AB, Nirschl CJ, Kochel CM, Nirschl TR, Francisca BJ, Velarde E, et al. Stereotactic Radiation Therapy Augments Antigen-Specific PD-1-Mediated Anti-Tumor Immune Responses via Cross- Presentation of Tumor Antigen. 2016;25(3):289–313.
18 Deng L, Weichselbaum RR, Fu Y, Deng L, Liang H, Burnette B, et al. Irradiation and anti – PD-L1 treatment synergistically promote antitumor immunity in mice Find the latest version : Irradiation and anti – PD-L1 treatment synergistically promote antitumor immunity in mice. J Clin Invest. 2014;124(2):687–95.
19 Wang Y, Deng W, Li N, Neri S, Sharma A, Jiang W, et al. Combining immunotherapy and radiotherapy for cancer treatment: Current challenges and future directions. Vol. 9, Frontiers in Pharmacology. Frontiers Media S.A.; 2018.
20 Galluzzi L, Chan TA, Kroemer G, Wolchok JD, López-Soto A. The hallmarks of successful anticancer immunotherapy. Sci Transl Med [Internet]. 2018 [cited 2019 Oct 26];10(459). Available from:
http://www.ncbi.nlm.nih.gov/pubmed/30232229
21 Aboudaram A, Modesto A, Chaltiel L, Gomez-Roca C, Boulinguez S, Sibaud V, et al. Concurrent radiotherapy for patients with metastatic melanoma and receiving anti-programmed-death 1 therapy: A safe and effective combination. Melanoma Res. 2017;27(5):485–91.
22 Koller KM, Mackley HB, Liu J, Wagner H, Talamo G, Schell TD, et al. Improved survival and complete response rates in patients with advanced melanoma treated with concurrent ipilimumab and radiotherapy versus ipilimumab alone. Cancer Biol Ther [Internet]. 2017;18(1):36–42. Available from:
http://dx.doi.org/10.1080/15384047.2016.1264543
23 Twyman-Saint Victor C, Rech AJ, Maity A, Rengan R, Pauken KE, Stelekati E, et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature. 2015 Apr 15;520(7547):373–7.
24 Hiniker SM, Reddy SA, Maecker HT, Subrahmanyam PB, Rosenberg-Hasson Y, Swetter SM, et al. A Prospective Clinical Trial Combining Radiation Therapy With Systemic Immunotherapy in Metastatic Melanoma. In: International Journal of Radiation Oncology Biology Physics. Elsevier Inc.; 2016. p. 578–88.
25 Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, et al. Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer. N Engl J Med [Internet]. 2017;NEJMoa1709937. Available from:
http://www.nejm.org/doi/10.1056/NEJMoa1709937
26 Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, et al. Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC. N Engl J Med. 2018 Dec;379(24):2342–50.
27. Shaverdian N, Lisberg AE, Bornazyan K, Veruttipong D, Goldman JW, Formenti SC, et al. Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer. Lancet Oncol. 2017;18(7):895–903.
28 Eckert F, Fietkau R, Fokas E, Gaipl U, Hecht M, Krause M. Stellungnahme zur Strahlentherapie in Kombination mit Immuntherapie. Dtsch Gesellschaft für Radioonkologie. 2018;
29 Chicas-Sett R, Morales-Orue I, Castilla-Martinez J, Zafra-Martin J, Kannemann A, Blanco J, et al. Stereotactic ablative radiotherapy combined with immune checkpoint inhibitors reboots the immune response assisted by immunotherapy in metastatic lung cancer: A systematic review. Int J Mol Sci. 2019;20(9).
30 Govindan R, Szczesna A, Ahn M-J, Schneider C-P, Gonzalez Mella PF, Barlesi F, et al. Phase III Trial of Ipilimumab Combined With Paclitaxel and Carboplatin in Advanced Squamous Non-Small-Cell Lung Cancer. J Clin Oncol [Internet]. 2017 Oct 20 [cited 2019 Oct 21];35(30):3449–57. Available from:
http://www.ncbi.nlm.nih.gov/pubmed/28854067
31 Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, et al. Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC. N Engl J Med. 2018;379(24):2342–50.
32. Tang C, Welsh JW, De Groot P, Massarelli E, Chang JY, Hess KR, et al. Ipilimumab with stereotactic ablative radiation therapy: Phase I results and immunologic correlates from peripheral T-cells HHS Public Access. Clin Cancer Res. 2017;23(6):1388–96.
33 Welsh JW, Tang C, de Groot P, Naing A, Raju U, Shaaban S, et al. Phase 2 5-Arm Trial of Ipilimumab Plus Lung or Liver Stereotactic Radiation for Patients with Advanced Malignancies. Int J Radiat Oncol. 2017 Dec;99(5):1315.
34 Belluomini L, Fiorica F, Frassoldati A. Immune Checkpoint Inhibitors and Radiotherapy in NSCLC Patients: Not Just a Fluke. Oncol Ther [Internet]. 2019;7(1):83–91. Available from:
https://doi.org/10.1007/s40487-019-0092-z
35 Kwon ED, Drake CG, Scher HI, Fizazi K, Bossi A, van den Eertwegh AJM, et al. Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 2014 Jun;15(7):700–12.
36 Manukian G, Bar-Ad V, Lu B, Argiris A, Johnson JM. Combining radiation and immune checkpoint blockade in the treatment of head and neck squamous cell carcinoma. Vol. 9, Frontiers in Oncology. Frontiers Media S.A.; 2019.
37 Theelen WSME, Peulen HMU, Lalezari F, Van Der Noort V, De Vries JF, Aerts JGJV, et al. Phase II 5-arm trial of ipilimumab plus lung or liver stereotactic radiation for patients with advanced malignancies. Int J Radiat Oncol Biol Phys. 2017;(99):1315.
38 Luke JJ, Lemons JM, Karrison TG, Pitroda SP, Melotek JM, Zha Y, et al. Safety and clinical activity of pembrolizumab and multisite stereotactic body radiotherapy in patients with advanced solid tumors. J Clin Oncol. 2018 Jun 1;36(16):1611–8.
39 Sun XS, Sire C, Tao Y, Martin L, Alfonsi M, Prevost JB, et al. A phase II randomized trial of pembrolizumab versus cetuximab, concomitant with radiotherapy (RT) in locally advanced (LA) squamous cell carcinoma of the head and neck (SCCHN): First results of the GORTEC 2015-01 “PembroRad” trial. J Clin Oncol. 2018 May 20;36(15_suppl):6018–6018.
40 Papadopoulos KP, Johnson ML, Lockhart AC, Moore K, Falchook GS, Formenti SC, et al. First-In-Human Study of Cemiplimab Alone or in Combination with Radiotherapy and/or Low-dose Cyclophosphamide in Patients with Advanced Malignancies. Clin Cancer Res. 2020;26(5):1025–33.
41 Tao Y, Auperin A, Sun XS, Sire C, Martin L, Bera G, et al. Avelumab-cetuximab-radiotherapy (RT) versus standards of care (SoC) in locally advanced squamous cell carcinoma of the head and neck (SCCHN): Safety phase of the randomized trial GORTEC 2017-01 (REACH). J Clin Oncol. 2018 May 20;36(15_suppl):6076–6076.
42 Levy A, Massard C, Soria JC, Deutsch E. Concurrent irradiation with the anti-programmed cell death ligand-1 immune checkpoint blocker durvalumab: Single centre subset analysis from a phase 1/2 trial. Eur J Cancer. 2016 Nov 1;68:156–62.